Answers are grounded in this paper and cite their sources.
Compared to SMBG, rt-CGM is highly likely to be a cost-effective intervention for patients living with insulin-treated T2D in Spain.
No takes yet. Share an insight, caveat, or question.
Merino-Torres et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: